Obtained ex-US Regulatory Clearance for DT-818, a Potentially Best-in-Disease Treatment for Myotonic Dystrophy Type-1 (DM1) Trials of DT-216P2 ...

AOC 1001 consists of a proprietary monoclonal antibody that binds to transferrin receptor 1 conjugated with a small interfering RNA. The Food and Drug Administration (FDA) has granted Fast Track ...

Using brain organoids, researchers discover mutational commonalities between muscular dystrophy type 1 and Rett syndrome, suggesting the potential of a similar treatment for both. Myotonic dystrophy ...

Dyne Therapeutics, Inc. (($DYN)) announced an update on their ongoing clinical study. Dyne Therapeutics, Inc. is conducting a clinical study ...

Researchers focused on Myotonic Dystrophy 1 heart problems are testing a novel approach to restore normal function. Myotonic Dystrophy Type 1 (DM1) is the most common adult-onset form of muscular ...

Dyne Therapeutics announces FDA Fast Track designation for DYNE-101, targeting myotonic dystrophy type 1 with potential accelerated approval in 2026. Dyne Therapeutics has announced that its ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio A Southern California biopharmaceutical ...

Please provide your email address to receive an email when new articles are posted on . The FDA has granted fast-track designation to an investigational antisense oligonucleotide to treat individuals ...

DM1 primarily affects skeletal and cardiac muscle and is characterized by muscle weakness, difficulty breathing, and cognitive and behavioral impairment. The Food and Drug Administration (FDA) has ...